Biocon continues expanding its biosimilar business across international markets, particularly in the US and Europe. The company is increasing investments in research and product development.
Growing demand for affordable healthcare solutions has strengthened the biosimilar segment globally. Biocon aims to benefit from this trend through strategic collaborations and product launches.
Experts believe the company’s focus on innovation and global expansion could support long-term revenue growth in the pharmaceutical sector.
